Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS)

Background  The TaqIB polymorphism in the cholesteryl ester transfer protein (CETP) gene is associated with HDL‐C, progression of coronary artery disease (CAD) and response to pravastatin treatment in men with angiographically proven CAD (REGRESS). We hypothesized that differences in CETP concentration could explain these associations and now investigated whether CETP concentration is an independent determinant of these parameters.

[1]  Johnf . Thompson,et al.  Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease Published, JLR Papers in Press, March 16, 2003. DOI 10.1194/jlr.R200018-JLR200 , 2003, Journal of Lipid Research.

[2]  F. Cambien,et al.  Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[3]  R. Stolk,et al.  Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. , 2003, Diabetes care.

[4]  A. Zwinderman,et al.  Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-->A polymorphism and a novel promoter variant are independently associated with CETP concentration. , 2003, Human molecular genetics.

[5]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[6]  T. Pedersen.  Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management. , 2001, The American journal of cardiology.

[7]  L. Li,et al.  Serum cholesteryl ester transfer protein concentrations in healthy Chinese subjects and cardio-cerebrovascular disease patients. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[8]  S. Yamashita,et al.  Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. , 2000, Biochimica et biophysica acta.

[9]  S. Yamashita,et al.  Pros and cons of inhibiting cholesteryl ester transfer protein , 2000, Current opinion in lipidology.

[10]  J. Fruchart,et al.  Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. , 2000, Atherosclerosis.

[11]  G. Luc,et al.  Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol. , 2000, Atherosclerosis.

[12]  K. Wakitani,et al.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.

[13]  P. Wilson,et al.  Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[14]  H. Mabuchi,et al.  Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. , 1999, Atherosclerosis.

[15]  P. Barter,et al.  Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. , 1998, Atherosclerosis.

[16]  R. Dullaart,et al.  Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. , 1998, Atherosclerosis.

[17]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[18]  J. Boer,et al.  Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[19]  B. Föger,et al.  Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[20]  D. Arveiler,et al.  Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. , 1995, The Journal of clinical investigation.

[21]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[22]  H. Mabuchi,et al.  Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. , 1994, The Journal of clinical investigation.

[23]  A. Tall,et al.  Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles. , 1993, The Journal of biological chemistry.

[24]  G. Ponsin,et al.  Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. , 1993, Atherosclerosis.

[25]  後藤 章友.  Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects : a study based on coronary angiography , 2003 .

[26]  M. Farnier,et al.  Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[27]  A. Tall,et al.  Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. , 1990, The Journal of clinical investigation.